Yong Gu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yong Gu has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Tao Yang
Department of Endocrinology and Metabolism, The First Affiliated Hospital with Nanjing Medical University, China
6 shared publications Hang Zhao
Department of Endocrinology & Metabolism, The First Affiliated Hospital with Nanjing Medical University
3 shared publicationsHeng Chen
Department of Endocrinology & Metabolism, The First Affiliated Hospital with Nanjing Medical University
3 shared publicationsLingling Bian
Department of Endocrinology & Metabolism, The First Affiliated Hospital with Nanjing Medical University
3 shared publicationsMei Zhang
Department of Endocrinology & Metabolism, The First Affiliated Hospital with Nanjing Medical University
3 shared publications- Mei Zhang
Department of Endocrinology, The First Affiliated Hospital with Nanjing Medical University, Nanjing Medical University, Nanjing, P.R. China
3 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1933235
Hepatic steatosis is associated with postprandial dysglycemia in type 1 diabetes: insights from dual-modality liver assessment
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized in type 1 diabetes (T1D), yet its relationship with dynamic glycemic abnormalities and the metabolic pathways underlying these associations remains incompletely understood. We investigated the associations of hepatic steatosis with conventional and continuous glucose monitoring (CGM)-derived glycemic measures in T1D and explored the potential roles of circulating insulin-like growth factor-1 (IGF-1) and insulin resistance. Methods: This cross-sectional study included 231 individuals with T1D who underwent hepatic steatosis assessment using ultrasonography and controlled attenuation parameter (CAP). Glycemic status was characterized using glycated hemoglobin (HbA1c), fasting plasma glucose, 1,5-anhydroglucitol (1,5-AG), and, in 142 participants, at least 72 h of valid CGM under standardized inpatient conditions. Multivariable linear regression, false discovery rate correction, and exploratory serial mediation analyses were performed. Results: Ultrasound-defined MASLD was present in 50 participants (21.6%). After multivariable adjustment, ultrasound-defined MASLD and greater CAP were consistently associated with lower 1,5-AG concentrations and less favorable CGM profiles, including higher 2-hour postprandial glucose, glucose peak, mean glucose, glucose management indicator, and time above range, together with lower time in range, whereas fasting glucose was not significantly associated with hepatic steatosis. Hepatic steatosis was also associated with lower circulating IGF-1 concentrations and greater insulin resistance across multiple surrogate indices. In exploratory serial mediation analysis using TG/HDL-C as the primary insulin resistance measure, the combined indirect association through IGF-1 and insulin resistance accounted for 82.6% of the association between MASLD and lower 1,5-AG concentrations, with consistent patterns observed using alternative insulin resistance indices. Conclusions: Hepatic steatosis in T1D is independently associated with a distinct dysglycemic phenotype characterized particularly by short-term and postprandial hyperglycemia. Concurrent differences in circulating IGF-1 and insulin sensitivity may statistically account for a substantial proportion of this association. These findings support hepatic steatosis as a clinically relevant metabolic comorbidity in T1D and warrant prospective studies to clarify the underlying temporal and biological relationships.
- 27 October 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1933235
Open AccessHepatic steatosis is associated with postprandial dysglycemia in type 1 diabetes: insights from dual-modality liver assessment
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized in type 1 diabetes (T1D), yet its relationship with dynamic glycemic abnormalities and the metabolic pathways underlying these associations remains incompletely understood. We investigated the associations of hepatic steatosis with conventional and continuous glucose monitoring (CGM)-derived glycemic measures in T1D and explored the potential roles of circulating insulin-like growth factor-1 (IGF-1) and insulin resistance. Methods: This cross-sectional study included 231 individuals with T1D who underwent hepatic steatosis assessment using ultrasonography and controlled attenuation parameter (CAP). Glycemic status was characterized using glycated hemoglobin (HbA1c), fasting plasma glucose, 1,5-anhydroglucitol (1,5-AG), and, in 142 participants, at least 72 h of valid CGM under standardized inpatient conditions. Multivariable linear regression, false discovery rate correction, and exploratory serial mediation analyses were performed. Results: Ultrasound-defined MASLD was present in 50 participants (21.6%). After multivariable adjustment, ultrasound-defined MASLD and greater CAP were consistently associated with lower 1,5-AG concentrations and less favorable CGM profiles, including higher 2-hour postprandial glucose, glucose peak, mean glucose, glucose management indicator, and time above range, together with lower time in range, whereas fasting glucose was not significantly associated with hepatic steatosis. Hepatic steatosis was also associated with lower circulating IGF-1 concentrations and greater insulin resistance across multiple surrogate indices. In exploratory serial mediation analysis using TG/HDL-C as the primary insulin resistance measure, the combined indirect association through IGF-1 and insulin resistance accounted for 82.6% of the association between MASLD and lower 1,5-AG concentrations, with consistent patterns observed using alternative insulin resistance indices. Conclusions: Hepatic steatosis in T1D is independently associated with a distinct dysglycemic phenotype characterized particularly by short-term and postprandial hyperglycemia. Concurrent differences in circulating IGF-1 and insulin sensitivity may statistically account for a substantial proportion of this association. These findings support hepatic steatosis as a clinically relevant metabolic comorbidity in T1D and warrant prospective studies to clarify the underlying temporal and biological relationships.
- Open Access
- 26 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1832672
From islet to blood: macrophage remodeling signatures for diagnosis and risk stratification in type 1 diabetes
Background: Type 1 diabetes (T1D) is an autoimmune disease characterized by progressive β-cell destruction, yet current risk stratification tools, which rely mainly on genetic susceptibility and autoantibody profiles, remain insufficient for accurately predicting disease progression. We aimed to characterize macrophage-related inflammatory transcriptional activity in T1D and to develop peripheral blood–based biomarkers for diagnosis and risk stratification. Methods: We integrated bulk RNA-seq, single-cell RNA-seq, and spatial transcriptomic data from human islets with public and in-house peripheral blood transcriptomic datasets. Macrophage heterogeneity and remodeling trajectories were analyzed in the islet microenvironment, and machine learning was used to derive tissue- and blood-based proinflammatory macrophage-related genes (PMRG). Diagnostic and prognostic models were then constructed and validated in peripheral blood cohorts, including a longitudinal islet autoimmunity (IA) cohort. SHAP analysis was applied to improve model interpretability. Independent PBMC RT-qPCR and mouse pancreatic immunofluorescence were performed to validate selected PMRG-related genes. Results: T1D islets showed marked immune remodeling with myeloid enrichment and five distinct macrophage subtypes. Pseudotime analysis identified a pro-inflammatory macrophage trajectory and 265 PMRGs, from which a 9-gene islet-derived PMRG (iPMRG) was obtained. Spatial transcriptomics supported the association of iPMRG-high macrophage signals with disrupted β-cell regions, and CellChat analysis inferred altered inflammatory communication programs. In peripheral blood mononuclear cells (PBMCs), the iPMRG-based diagnostic classifier distinguished T1D from healthy controls with an optimism-corrected AUC of 0.736. For prognosis, a 15-gene prognostic PMRGs was used to construct a risk score that, when integrated with clinical variables, predicted progression from IA to clinical T1D with time-dependent AUCs of 0.825, 0.814, and 0.860 at 12, 36, and 60 months, respectively. SHAP analysis identified the PMRG risk score as the dominant predictor and highlighted six core driver genes (PID1, TFPI2, SERPINB2, SOX4, DUSP2, and MT1X). The computational findings were further supported by independent validation in PBMCs and mouse pancreatic tissues. Conclusions: Our study highlights the heterogeneous and dynamic nature of macrophage remodeling in the T1D islet microenvironment, which is translated into accessible peripheral blood signatures. The resulting diagnostic and prognostic models provide an interpretable framework for T1D risk stratification and may support future strategies for earlier detection and precision prevention.
- 26 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1832672
Open AccessFrom islet to blood: macrophage remodeling signatures for diagnosis and risk stratification in type 1 diabetes
Background: Type 1 diabetes (T1D) is an autoimmune disease characterized by progressive β-cell destruction, yet current risk stratification tools, which rely mainly on genetic susceptibility and autoantibody profiles, remain insufficient for accurately predicting disease progression. We aimed to characterize macrophage-related inflammatory transcriptional activity in T1D and to develop peripheral blood–based biomarkers for diagnosis and risk stratification. Methods: We integrated bulk RNA-seq, single-cell RNA-seq, and spatial transcriptomic data from human islets with public and in-house peripheral blood transcriptomic datasets. Macrophage heterogeneity and remodeling trajectories were analyzed in the islet microenvironment, and machine learning was used to derive tissue- and blood-based proinflammatory macrophage-related genes (PMRG). Diagnostic and prognostic models were then constructed and validated in peripheral blood cohorts, including a longitudinal islet autoimmunity (IA) cohort. SHAP analysis was applied to improve model interpretability. Independent PBMC RT-qPCR and mouse pancreatic immunofluorescence were performed to validate selected PMRG-related genes. Results: T1D islets showed marked immune remodeling with myeloid enrichment and five distinct macrophage subtypes. Pseudotime analysis identified a pro-inflammatory macrophage trajectory and 265 PMRGs, from which a 9-gene islet-derived PMRG (iPMRG) was obtained. Spatial transcriptomics supported the association of iPMRG-high macrophage signals with disrupted β-cell regions, and CellChat analysis inferred altered inflammatory communication programs. In peripheral blood mononuclear cells (PBMCs), the iPMRG-based diagnostic classifier distinguished T1D from healthy controls with an optimism-corrected AUC of 0.736. For prognosis, a 15-gene prognostic PMRGs was used to construct a risk score that, when integrated with clinical variables, predicted progression from IA to clinical T1D with time-dependent AUCs of 0.825, 0.814, and 0.860 at 12, 36, and 60 months, respectively. SHAP analysis identified the PMRG risk score as the dominant predictor and highlighted six core driver genes (PID1, TFPI2, SERPINB2, SOX4, DUSP2, and MT1X). The computational findings were further supported by independent validation in PBMCs and mouse pancreatic tissues. Conclusions: Our study highlights the heterogeneous and dynamic nature of macrophage remodeling in the T1D islet microenvironment, which is translated into accessible peripheral blood signatures. The resulting diagnostic and prognostic models provide an interpretable framework for T1D risk stratification and may support future strategies for earlier detection and precision prevention.
- Open Access
- 2 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0341915
Association between carbohydrate quality and glycemic control in individuals with type 1 diabetes: A cross-sectional and meal-based analysis
The aim of the study was to investigate the association between the quality of carbohydrates in the diet and glycemic control in individuals with Type 1 Diabetes (T1D). In this cross-sectional study, a dietary survey involving 155 individuals with T1D used a food frequency questionnaire (FFQ) and 3-day dietary records from 65 individuals to analyze 538 meals. The relationship between short-term dietary factors and postprandial glycemic fluctuations was evaluated by a mixed-effects model. The FFQ survey indicated that a higher intake of dietary fiber was associated with better long-term glycemic control (HbA1c≤6.5%) in T1D individuals (OR=1.101, p = 0.031). Analysis of 3-day dietary records and continuous glucose monitoring (CGM) data showed an inverse correlation between whole grain intake and postprandial glycemic variability, measured by standard deviation (SD), large amplitude of glycemic excursions (LAGE) and mean amplitude of glycemic excursions (MAGE) (Est. = −0.83, p < 0.01; Est. = −2.4, p < 0.01; Est. = −1.47, p = 0.04). Specifically, blood glucose fluctuations (SD, LAGE, MAGE) were more significant after lunch (p < 0.05), and these fluctuations were negatively related to the intake of whole grains (Est. = −0.45, p = 0.02; Est. = −1.52, p = 0.01; Est. = −1.39, p < 0.01). From a long-term glycemic control perspective, higher dietary fiber intake appears to be associated with improved HbA1c levels, while in terms of short-term glycemic variability, increased whole grain consumption is associated with reduced glucose fluctuations. However, as a cross-sectional analysis, these findings represent observational associations rather than causal evidence. Further validation through prospective cohorts and randomized trials is needed to assess clinical applicability.
- 2 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0341915
Open AccessAssociation between carbohydrate quality and glycemic control in individuals with type 1 diabetes: A cross-sectional and meal-based analysis
The aim of the study was to investigate the association between the quality of carbohydrates in the diet and glycemic control in individuals with Type 1 Diabetes (T1D). In this cross-sectional study, a dietary survey involving 155 individuals with T1D used a food frequency questionnaire (FFQ) and 3-day dietary records from 65 individuals to analyze 538 meals. The relationship between short-term dietary factors and postprandial glycemic fluctuations was evaluated by a mixed-effects model. The FFQ survey indicated that a higher intake of dietary fiber was associated with better long-term glycemic control (HbA1c≤6.5%) in T1D individuals (OR=1.101, p = 0.031). Analysis of 3-day dietary records and continuous glucose monitoring (CGM) data showed an inverse correlation between whole grain intake and postprandial glycemic variability, measured by standard deviation (SD), large amplitude of glycemic excursions (LAGE) and mean amplitude of glycemic excursions (MAGE) (Est. = −0.83, p < 0.01; Est. = −2.4, p < 0.01; Est. = −1.47, p = 0.04). Specifically, blood glucose fluctuations (SD, LAGE, MAGE) were more significant after lunch (p < 0.05), and these fluctuations were negatively related to the intake of whole grains (Est. = −0.45, p = 0.02; Est. = −1.52, p = 0.01; Est. = −1.39, p < 0.01). From a long-term glycemic control perspective, higher dietary fiber intake appears to be associated with improved HbA1c levels, while in terms of short-term glycemic variability, increased whole grain consumption is associated with reduced glucose fluctuations. However, as a cross-sectional analysis, these findings represent observational associations rather than causal evidence. Further validation through prospective cohorts and randomized trials is needed to assess clinical applicability.
- 23 May 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (1) , 180-198
Impaired Glucagon Suppression Accompanied by Liver Fat Accumulation Mediated Worse Blood Glucose Control in Patients With T2D
Context: Metabolic dysfunction–associated steatotic liver disease is prevalent in type 2 diabetes (T2D) and exacerbates hyperglycemia, but its impact on postprandial glucagon suppression remains unclear. Objective: To investigate the association between hepatic steatosis and impaired glucagon suppression during oral glucose tolerance tests (OGTTs), and to evaluate the mediating role of glucagon dysregulation in linking liver fat to glycemic control. Methods: In this cross-sectional study, 604 patients with T2D underwent liver fat quantification via the FibroScan Pro controlled attenuation parameter (CAP) and liver ultrasound. Postprandial glucagon suppression was assessed during 180-minute OGTTs (0, 30, 60, 120, 180 minutes), with continuous glucose monitoring (CGM) in 287 participants. Glucagon suppression was calculated for early (0-30 minutes), late (30-180 minutes), and overall (0-180 minutes) phases. Multivariable regression and mediation analyses tested associations between CAP, glucagon dynamics, and CGM-derived glycemic profiles. Results: Patients with T2D with MASLD (CAP ≥238 dB/m, n = 414) exhibited significantly impaired glucagon suppression compared to non-MASLD controls (n = 190) across all phases (all P < .05). Each 1-SD CAP increase independently predicted attenuated dose-dependent suppression in all phases (standardized β = 0.183–0.303, P < .001). Males showed greater suppression impairment than females and stronger CAP-associated dysregulation. Mediation analysis revealed that glucagon suppression mediated 14.9% to 33.9% of the adverse effects of liver fat on hyperglycemia. Conclusion: Liver fat accumulation in T2D is strongly associated with defective postprandial glucagon suppression, particularly in males, which mediates nearly one-third of its detrimental impact on glycemic control. Targeting hepatic steatosis and glucagon signaling may offer novel therapeutic strategies for T2D management.
- 23 May 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (1) , 180-198
Impaired Glucagon Suppression Accompanied by Liver Fat Accumulation Mediated Worse Blood Glucose Control in Patients With T2D
Context: Metabolic dysfunction–associated steatotic liver disease is prevalent in type 2 diabetes (T2D) and exacerbates hyperglycemia, but its impact on postprandial glucagon suppression remains unclear. Objective: To investigate the association between hepatic steatosis and impaired glucagon suppression during oral glucose tolerance tests (OGTTs), and to evaluate the mediating role of glucagon dysregulation in linking liver fat to glycemic control. Methods: In this cross-sectional study, 604 patients with T2D underwent liver fat quantification via the FibroScan Pro controlled attenuation parameter (CAP) and liver ultrasound. Postprandial glucagon suppression was assessed during 180-minute OGTTs (0, 30, 60, 120, 180 minutes), with continuous glucose monitoring (CGM) in 287 participants. Glucagon suppression was calculated for early (0-30 minutes), late (30-180 minutes), and overall (0-180 minutes) phases. Multivariable regression and mediation analyses tested associations between CAP, glucagon dynamics, and CGM-derived glycemic profiles. Results: Patients with T2D with MASLD (CAP ≥238 dB/m, n = 414) exhibited significantly impaired glucagon suppression compared to non-MASLD controls (n = 190) across all phases (all P < .05). Each 1-SD CAP increase independently predicted attenuated dose-dependent suppression in all phases (standardized β = 0.183–0.303, P < .001). Males showed greater suppression impairment than females and stronger CAP-associated dysregulation. Mediation analysis revealed that glucagon suppression mediated 14.9% to 33.9% of the adverse effects of liver fat on hyperglycemia. Conclusion: Liver fat accumulation in T2D is strongly associated with defective postprandial glucagon suppression, particularly in males, which mediates nearly one-third of its detrimental impact on glycemic control. Targeting hepatic steatosis and glucagon signaling may offer novel therapeutic strategies for T2D management.
- Open Access
- 31 March 2025
- Published by Springer Nature in BMC Medicine
- Vol. 23 (1) , 1-24
Enhancing anti-CD3 mAb-mediated diabetes remission in autoimmune diabetes through regulation of dynamin-related protein 1(Drp1)-mediated mitochondrial dynamics in exhausted CD8+T-cell subpopulations
Antigen-specific immunotherapy shows potential for inducing long-term immune tolerance in type 1 diabetes (T1D), yet its clinical application is hampered by uncertainty regarding dominant epitopes. Conversely, non-antigen-specific treatments such as anti-CD3 monoclonal antibodies (mAbs) present a more straightforward approach but struggle to maintain tolerance after treatment. Addressing these issues is critical for advancing T1D therapies. The phenotypic and metabolic properties of two subsets of exhausted CD8+ T cells were analyzed in both humans and NOD mice. T-cell receptor (TCR) diversity and Bulk RNA sequencing provided insights into the transcriptomic profiles and TCR reactivity of these cells. Mechanistic studies were conducted using the HEK-293 T cell line and primary cells. Single-cell RNA sequencing (scRNA-seq) was applied to evaluate the characteristics of different CD8+ T cell subsets following two types of immunotherapies. In NY8.3 mice, the effect of mitochondrial fission inhibitors on immunotherapy results was evaluated. Final validation was carried out with peripheral blood mononuclear cells (PBMCs) from T1D patients. Our study reveals the diversity of two distinct exhausted CD8+ T cell subsets in T1D through flow cytometry, highlighting unique clinical features, phenotypes, and functions. Notable differences in TCR reactivity and metabolic pathways between these subsets were identified through TCR sequencing and transcriptomic analyses in NOD mice. Both antigen-specific and non-antigen-specific stimuli produced unique exhausted CD8+ T cell subsets. Our research identified leucine-rich repeat kinase 2 (Lrrk2) as a key regulator of mitochondrial fission, influencing the interconversion of exhausted CD8+ T cell subsets by phosphorylating dynamin-related protein 1 (DRP1) at serine 637 (Ser637) and serine 616 (Ser616). scRNA-seq confirmed that antigen-specific immunotherapy effectively suppresses T cell signaling, induces exhaustion, and promotes the development of terminally exhausted T (TEX) cells. Mitochondrial division inhibitor 1 (Mdivi-1) enhanced the therapeutic effect of anti-CD3 mAb treatment by promoting the development of more TEX cells. Our results point to a new immunotherapeutic approach that targets exhausted CD8+ T cells’ energy metabolism, offering valuable insights for advancing clinical strategies in T1D therapy.
- 31 March 2025
- Published by Springer Nature in BMC Medicine
- Vol. 23 (1) , 1-24
Open AccessEnhancing anti-CD3 mAb-mediated diabetes remission in autoimmune diabetes through regulation of dynamin-related protein 1(Drp1)-mediated mitochondrial dynamics in exhausted CD8+T-cell subpopulations
Antigen-specific immunotherapy shows potential for inducing long-term immune tolerance in type 1 diabetes (T1D), yet its clinical application is hampered by uncertainty regarding dominant epitopes. Conversely, non-antigen-specific treatments such as anti-CD3 monoclonal antibodies (mAbs) present a more straightforward approach but struggle to maintain tolerance after treatment. Addressing these issues is critical for advancing T1D therapies. The phenotypic and metabolic properties of two subsets of exhausted CD8+ T cells were analyzed in both humans and NOD mice. T-cell receptor (TCR) diversity and Bulk RNA sequencing provided insights into the transcriptomic profiles and TCR reactivity of these cells. Mechanistic studies were conducted using the HEK-293 T cell line and primary cells. Single-cell RNA sequencing (scRNA-seq) was applied to evaluate the characteristics of different CD8+ T cell subsets following two types of immunotherapies. In NY8.3 mice, the effect of mitochondrial fission inhibitors on immunotherapy results was evaluated. Final validation was carried out with peripheral blood mononuclear cells (PBMCs) from T1D patients. Our study reveals the diversity of two distinct exhausted CD8+ T cell subsets in T1D through flow cytometry, highlighting unique clinical features, phenotypes, and functions. Notable differences in TCR reactivity and metabolic pathways between these subsets were identified through TCR sequencing and transcriptomic analyses in NOD mice. Both antigen-specific and non-antigen-specific stimuli produced unique exhausted CD8+ T cell subsets. Our research identified leucine-rich repeat kinase 2 (Lrrk2) as a key regulator of mitochondrial fission, influencing the interconversion of exhausted CD8+ T cell subsets by phosphorylating dynamin-related protein 1 (DRP1) at serine 637 (Ser637) and serine 616 (Ser616). scRNA-seq confirmed that antigen-specific immunotherapy effectively suppresses T cell signaling, induces exhaustion, and promotes the development of terminally exhausted T (TEX) cells. Mitochondrial division inhibitor 1 (Mdivi-1) enhanced the therapeutic effect of anti-CD3 mAb treatment by promoting the development of more TEX cells. Our results point to a new immunotherapeutic approach that targets exhausted CD8+ T cells’ energy metabolism, offering valuable insights for advancing clinical strategies in T1D therapy.
- Open Access
- 4 September 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (17) , 2859
Identification of Autoantibodies to a Hybrid Insulin Peptide in Type 1 Diabetes
Type 1 diabetes (T1D) is a chronic autoimmune disease that attacks the insulin-producing b cells of the pancreatic islets. Autoantibodies to b cell proteins typically appear in the circulation years before disease onset, and serve as the most accurate biomarkers of T1D risk. Our laboratory has recently discovered novel b cell proteins comprising hybrid proinsulin:islet amyloid polypeptide peptides (IAPP). T cells from a diabetic mouse model and T1D patients are activated by these hybrid peptides. In this study, we asked whether these hybrid molecules could serve as antigens for autoantibodies in T1D and prediabetic patients. We analyzed sera from T1D patients, prediabetics and healthy age-matched donors. Using a highly sensitive electrochemiluminescence assay, sera were screened for binding to recombinant proinsulin:IAPP probes or truncated derivatives. Our results show that sera from T1D patients contain antibodies that bind larger hybrid proinsulin:IAPP probes, but not proinsulin or insulin, at significantly increased frequencies compared to normal donors. Examination of sera from prediabetic patients confirms titers of antibodies to these hybrid probes in more than 80% of individuals, often before seroconversion. These results suggest that hybrid insulin peptides are common autoantigens in T1D and prediabetic patients, and that antibodies to these peptides may serve as valuable early biomarkers of the disease.
- 4 September 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (17) , 2859
Open AccessIdentification of Autoantibodies to a Hybrid Insulin Peptide in Type 1 Diabetes
Type 1 diabetes (T1D) is a chronic autoimmune disease that attacks the insulin-producing b cells of the pancreatic islets. Autoantibodies to b cell proteins typically appear in the circulation years before disease onset, and serve as the most accurate biomarkers of T1D risk. Our laboratory has recently discovered novel b cell proteins comprising hybrid proinsulin:islet amyloid polypeptide peptides (IAPP). T cells from a diabetic mouse model and T1D patients are activated by these hybrid peptides. In this study, we asked whether these hybrid molecules could serve as antigens for autoantibodies in T1D and prediabetic patients. We analyzed sera from T1D patients, prediabetics and healthy age-matched donors. Using a highly sensitive electrochemiluminescence assay, sera were screened for binding to recombinant proinsulin:IAPP probes or truncated derivatives. Our results show that sera from T1D patients contain antibodies that bind larger hybrid proinsulin:IAPP probes, but not proinsulin or insulin, at significantly increased frequencies compared to normal donors. Examination of sera from prediabetic patients confirms titers of antibodies to these hybrid probes in more than 80% of individuals, often before seroconversion. These results suggest that hybrid insulin peptides are common autoantigens in T1D and prediabetic patients, and that antibodies to these peptides may serve as valuable early biomarkers of the disease.
- Open Access
- 18 April 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14
Association of subclass distribution of insulin antibody with glucose control in insulin-treated type 2 diabetes mellitus: a retrospective observational study
Objective: To examine the distribution and effects of the subclass of insulin antibodies on glucose control and side events in patients with type 2 diabetes treated with premixed insulin analog.Methods: A total of 516 patients treated with premixed insulin analog were sequentially enrolled from the First Affiliated Hospital of Nanjing Medical University from June 2016 to August 2020. Subclass-specific insulin antibodies (IAs) (IgG1-4, IgA, IgD, IgE, and IgM) were detected in IA-positive patients by electrochemiluminescence. We analyzed glucose control, serum insulin, and insulin-related events between IA-positive and IA-negative groups, as well as among patients with different IA subclasses.Results: Overall, 98 of 516 subjects (19.0%) were positive for total IAs after premixed insulin analog therapy; of these participants, 92 had subclass IAs, and IgG-IA was the predominant subclass, followed by IgE-IA. IAs were associated with serum total insulin increase and local injection-site reactions but not glycemic control and hypoglycemia. In the subgroup analysis in patients with IA-positive, the IgE-IA and IA subclass numbers were more associated with increased serum total insulin levels. Additionally, IgE-IA might be correlated more strongly with local responses and weakly with hypoglycemia, while IgM-IA might be correlated more strongly with hypoglycemia.Conclusion: We concluded that IAs or IA subclasses might be associated with unfavorable events in patients receiving premixed insulin analog therapy, which can be used as an adjunctive monitoring indicator in clinical insulin trials.
- 18 April 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14
Open AccessAssociation of subclass distribution of insulin antibody with glucose control in insulin-treated type 2 diabetes mellitus: a retrospective observational study
Objective: To examine the distribution and effects of the subclass of insulin antibodies on glucose control and side events in patients with type 2 diabetes treated with premixed insulin analog.Methods: A total of 516 patients treated with premixed insulin analog were sequentially enrolled from the First Affiliated Hospital of Nanjing Medical University from June 2016 to August 2020. Subclass-specific insulin antibodies (IAs) (IgG1-4, IgA, IgD, IgE, and IgM) were detected in IA-positive patients by electrochemiluminescence. We analyzed glucose control, serum insulin, and insulin-related events between IA-positive and IA-negative groups, as well as among patients with different IA subclasses.Results: Overall, 98 of 516 subjects (19.0%) were positive for total IAs after premixed insulin analog therapy; of these participants, 92 had subclass IAs, and IgG-IA was the predominant subclass, followed by IgE-IA. IAs were associated with serum total insulin increase and local injection-site reactions but not glycemic control and hypoglycemia. In the subgroup analysis in patients with IA-positive, the IgE-IA and IA subclass numbers were more associated with increased serum total insulin levels. Additionally, IgE-IA might be correlated more strongly with local responses and weakly with hypoglycemia, while IgM-IA might be correlated more strongly with hypoglycemia.Conclusion: We concluded that IAs or IA subclasses might be associated with unfavorable events in patients receiving premixed insulin analog therapy, which can be used as an adjunctive monitoring indicator in clinical insulin trials.
- 8 December 2022
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 108 (6) , e326-e333
Combined Detection of Islet Autoantibodies for Clinical Diagnosis of Type 1 Diabetes in the Low-Prevalence Population
Context: Single positive islet autoantibodies (IAbs), sometimes detected in healthy individuals and patients with low-risk of developing type 1 diabetes (T1D), are considered to be irrelevant to the development of diabetes, making it difficult to diagnose and classify adult-onset diabetes. Objective: To determine the significance and clinical value of IAbs in T1D diagnosis in the low-prevalence population, and to explore whether an electrochemiluminescence IAb detection assay can improve the clinical utility of IAbs in the immunodiagnosis of T1D in the low-prevalence population. Methods: A total of 633 newly diagnosed patients with adult-onset diabetes (≥18 years old) were divided into 2 groups according to their clinical phenotypes: 575 patients with age at diagnosis ≥35 years and body mass index (BMI) ≥ 24 kg/m2 were considered a low-prevalence population (population with a low prevalence of T1D) and the other 58 patients were considered a high-prevalence population. All the samples from 633 participants were tested with IAbs using standard radiobinding assays (RBAs) and electrochemiluminescence (ECL) assays in parallel. Results: Compared with the high-prevalence population, fewer positive IAbs (94/575, 16.3% vs 28/58, 48.3%) were detected in the low-prevalence population, and more of whom (69/94, 73.4% vs 9/28, 32.2%) were positive for a single IAb, with glutamate decarboxylase antibodies being the most prevalent single IAb. Single-IAb detection in the low-prevalence population did not always suggest the T1D phenotype. Combined detection of IAbs by RBA and ECL assay had a significant clinical utility to distinguish autoimmune diabetes in the low-prevalence population with low BMI, poor β-cell function at the diagnosis, and an accelerated decline in β-cell function during the follow-up. Conclusion: Combined autoantibody detection by RBA and ECL assays improved differentiating autoimmune from nonautoimmune diabetes in the low-prevalence population.
- 8 December 2022
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 108 (6) , e326-e333
Combined Detection of Islet Autoantibodies for Clinical Diagnosis of Type 1 Diabetes in the Low-Prevalence Population
Context: Single positive islet autoantibodies (IAbs), sometimes detected in healthy individuals and patients with low-risk of developing type 1 diabetes (T1D), are considered to be irrelevant to the development of diabetes, making it difficult to diagnose and classify adult-onset diabetes. Objective: To determine the significance and clinical value of IAbs in T1D diagnosis in the low-prevalence population, and to explore whether an electrochemiluminescence IAb detection assay can improve the clinical utility of IAbs in the immunodiagnosis of T1D in the low-prevalence population. Methods: A total of 633 newly diagnosed patients with adult-onset diabetes (≥18 years old) were divided into 2 groups according to their clinical phenotypes: 575 patients with age at diagnosis ≥35 years and body mass index (BMI) ≥ 24 kg/m2 were considered a low-prevalence population (population with a low prevalence of T1D) and the other 58 patients were considered a high-prevalence population. All the samples from 633 participants were tested with IAbs using standard radiobinding assays (RBAs) and electrochemiluminescence (ECL) assays in parallel. Results: Compared with the high-prevalence population, fewer positive IAbs (94/575, 16.3% vs 28/58, 48.3%) were detected in the low-prevalence population, and more of whom (69/94, 73.4% vs 9/28, 32.2%) were positive for a single IAb, with glutamate decarboxylase antibodies being the most prevalent single IAb. Single-IAb detection in the low-prevalence population did not always suggest the T1D phenotype. Combined detection of IAbs by RBA and ECL assay had a significant clinical utility to distinguish autoimmune diabetes in the low-prevalence population with low BMI, poor β-cell function at the diagnosis, and an accelerated decline in β-cell function during the follow-up. Conclusion: Combined autoantibody detection by RBA and ECL assays improved differentiating autoimmune from nonautoimmune diabetes in the low-prevalence population.
- Open Access
- 1 January 2021
- Published by American Institute of Mathematical Sciences (AIMS) in Mathematical Biosciences and Engineering
- Vol. 18 (3) , 2675-2687
A novel numerical model of combination levels of C-peptide and insulin in coronary artery disease risk prediction
Objective Insulin resistance is a major risk factor for coronary artery disease (CAD). The C-peptide-to-insulin ratio (C/I) is associated with hepatic insulin clearance and insulin resistance. The current study was designed to establish a novel C/I index (CPIRI) model and provide early risk assessment of CAD. Methods A total of 865 adults diagnosed with new-onset diabetes mellitus (DM) within one year and 54 healthy controls (HC) were recruited to develop a CPIRI model. The CPIRI model was established with fasting C/I as the independent variable and homeostasis model assessment of insulin resistance (HOMA-IR) as the dependent variable. Associations between the CPIRI model and the severity of CAD events were also assessed in 45 hyperglycemic patients with CAD documented via coronary arteriography (CAG) and whom underwent stress echocardiography (SE) and exercise electrocardiography test (EET). Results Fasting C-peptide/insulin and HOMA-IR were hyperbolically correlated in DM patients and HC, and log(C/I) and log(HOMA-IR) were linearly and negatively correlated. The respective correlational coefficients were −0.83 (p < 0.001) and −0.76 (p < 0.001). The equations CPIRI(DM) = 670/(C/I)2.24 + 0.25 and CPIRI(HC) = 670/(C/I)2.24 − 1 (F = 1904.39, p < 0.001) were obtained. Patients with insulin resistance exhibited severe coronary artery impairment and myocardial ischemia. In CAD patients there was no significant correlation between insulin resistance and the number of vessels involved. Conclusions CPIRI can be used to effectively evaluate insulin resistance, and the combination of CPIRI and non-invasive cardiovascular examination is of great clinical value in the assessment of CAD.
- 1 January 2021
- Published by American Institute of Mathematical Sciences (AIMS) in Mathematical Biosciences and Engineering
- Vol. 18 (3) , 2675-2687
Open AccessA novel numerical model of combination levels of C-peptide and insulin in coronary artery disease risk prediction
Objective Insulin resistance is a major risk factor for coronary artery disease (CAD). The C-peptide-to-insulin ratio (C/I) is associated with hepatic insulin clearance and insulin resistance. The current study was designed to establish a novel C/I index (CPIRI) model and provide early risk assessment of CAD. Methods A total of 865 adults diagnosed with new-onset diabetes mellitus (DM) within one year and 54 healthy controls (HC) were recruited to develop a CPIRI model. The CPIRI model was established with fasting C/I as the independent variable and homeostasis model assessment of insulin resistance (HOMA-IR) as the dependent variable. Associations between the CPIRI model and the severity of CAD events were also assessed in 45 hyperglycemic patients with CAD documented via coronary arteriography (CAG) and whom underwent stress echocardiography (SE) and exercise electrocardiography test (EET). Results Fasting C-peptide/insulin and HOMA-IR were hyperbolically correlated in DM patients and HC, and log(C/I) and log(HOMA-IR) were linearly and negatively correlated. The respective correlational coefficients were −0.83 (p < 0.001) and −0.76 (p < 0.001). The equations CPIRI(DM) = 670/(C/I)2.24 + 0.25 and CPIRI(HC) = 670/(C/I)2.24 − 1 (F = 1904.39, p < 0.001) were obtained. Patients with insulin resistance exhibited severe coronary artery impairment and myocardial ischemia. In CAD patients there was no significant correlation between insulin resistance and the number of vessels involved. Conclusions CPIRI can be used to effectively evaluate insulin resistance, and the combination of CPIRI and non-invasive cardiovascular examination is of great clinical value in the assessment of CAD.
- Open Access
- 1 December 2019
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 67 (8) , 1103-1109
Investigate predictive capacity of in-hospital mortality of four severity score systems on critically ill patients with acute kidney injury
Although significant improvements have been achieved in the renal replacement therapy of acute kidney injury (AKI), the mortality of patients with AKI remains high. The aim of this study is to prospectively investigate the capacity of Acute Physiology and Chronic Health Evaluation version II (APACHE II), Simplified Acute Physiology Score version II (SAPS II), Sepsis-related Organ Failure Assessment (SOFA) and Acute Tubular Necrosis Individual Severity Index (ATN-ISI) to predict in-hospital mortality of critically ill patients with AKI. A prospective observational study was conducted in a university teaching hospital. 189 consecutive critically ill patients with AKI were selected according Risk, Injury, Failure, Loss, or End-stage kidney disease criteria. APACHE II, SAPS II, SOFA and ATN-ISI counts were obtained within the first 24 hours following admission. Receiver operating characteristic analyses (ROCs) were applied. Area under the ROC curve (AUC) was calculated. Sensitivity and specificity of in-hospital mortality prediction were calculated. In this study, the in-hospital mortality of critically ill patients with AKI was 37.04% (70/189). AUC of APACHE II, SAPS II, SOFA and ATN-ISI was 0.903 (95% CI 0.856 to 0.950), 0.893 (95% CI 0.847 to 0.940), 0.908 (95% CI 0.866 to 0.950) and 0.889 (95% CI 0.841 to 0.937) and sensitivity was 90.76%, 89.92%, 90.76% and 89.08% and specificity was 77.14%, 70.00%, 71.43% and 71.43%, respectively. In this study, it was found APACHE II, SAPS II, SOFA and ATN-ISI are reliable in-hospital mortality predictors of critically ill patients with AKI. Trial registration number: NCT00953992.
- 1 December 2019
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 67 (8) , 1103-1109
Open AccessInvestigate predictive capacity of in-hospital mortality of four severity score systems on critically ill patients with acute kidney injury
Although significant improvements have been achieved in the renal replacement therapy of acute kidney injury (AKI), the mortality of patients with AKI remains high. The aim of this study is to prospectively investigate the capacity of Acute Physiology and Chronic Health Evaluation version II (APACHE II), Simplified Acute Physiology Score version II (SAPS II), Sepsis-related Organ Failure Assessment (SOFA) and Acute Tubular Necrosis Individual Severity Index (ATN-ISI) to predict in-hospital mortality of critically ill patients with AKI. A prospective observational study was conducted in a university teaching hospital. 189 consecutive critically ill patients with AKI were selected according Risk, Injury, Failure, Loss, or End-stage kidney disease criteria. APACHE II, SAPS II, SOFA and ATN-ISI counts were obtained within the first 24 hours following admission. Receiver operating characteristic analyses (ROCs) were applied. Area under the ROC curve (AUC) was calculated. Sensitivity and specificity of in-hospital mortality prediction were calculated. In this study, the in-hospital mortality of critically ill patients with AKI was 37.04% (70/189). AUC of APACHE II, SAPS II, SOFA and ATN-ISI was 0.903 (95% CI 0.856 to 0.950), 0.893 (95% CI 0.847 to 0.940), 0.908 (95% CI 0.866 to 0.950) and 0.889 (95% CI 0.841 to 0.937) and sensitivity was 90.76%, 89.92%, 90.76% and 89.08% and specificity was 77.14%, 70.00%, 71.43% and 71.43%, respectively. In this study, it was found APACHE II, SAPS II, SOFA and ATN-ISI are reliable in-hospital mortality predictors of critically ill patients with AKI. Trial registration number: NCT00953992.